Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine

被引:27
作者
Balériaux, D
Colosimo, C
Ruscalleda, J
Korves, M
Schneider, G
Bohndorf, K
Bongartz, G
van Buchem, MA
Reiser, M
Sartor, K
Bourne, MW
Parizel, PM
Cherryman, GR
Salerio, I
La Noce, A
Pirovano, G
Kirchin, MA
Spinazzi, A
机构
[1] Hop Erasme, Clin Neuroradiol, B-1070 Brussels, Belgium
[2] Univ G DAnnunzio, Inst Radiol Sci, Chieti, Italy
[3] Hosp San Pablo de Barcelona, Dept Radiol, Barcelona, Spain
[4] Humboldt Univ, Fak Med, Inst Rontgendiagnost, D-1040 Berlin, Germany
[5] Univ Hosp, Dept Diagnost Radiol, Homburg, Germany
[6] Zent Klinikum, Klin Diagnost Radiol & Neuroradiol, Augsburg, Germany
[7] Kantonsspital Basel, Univ Klinikum, Dept Med Radiol, Basel, Switzerland
[8] Univ Leiden Hosp, Dept Diagnost Radiol, NL-2300 RC Leiden, Netherlands
[9] Univ Munich, Klinikum Grosshadern, Inst Radiol Diagnost, D-8000 Munich, Germany
[10] Univ Klinikum Heidelberg, Abt Neuroradiol, Heidelberg, Germany
[11] Univ Wales Hosp, Dept Diagnost Radiol, Cardiff CF4 4XW, S Glam, Wales
[12] Univ Ziekenhuis Antwerpen, Dept Radiol, Edegem, Belgium
[13] Univ Leicester, Sch Med, Leicester Royal Infirm, Dept Diagnost Radiol, Leicester, Leics, England
[14] Bracco Imaging Spa, Med Affairs Europe, Milan, Italy
关键词
gadobenate dimeglumine; Gd-BOPTA; MR imaging; CNS metastases; lesion detection;
D O I
10.1007/s002340100636
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Seventy-four patients with one to eight proven intraaxial brain metastases received a total cumulative dose of 0.2 mmol/kg bodyweight gadobenate dimeglumine, administered as sequential injections of 0.05, 0.05 and 0.1 mmol/kg over a 20-min period. MR imaging was performed before the first administration (T2- and T1-weighted sequences) and after each injection of contrast agent (T1-weighted sequences only). Quantitative assessment of images revealed significant (P < 0.01) dose-related increases in lesion-to-brain (L/B) ratio and percent enhancement of lesion signal intensity. Qualitative assessment by two independent, blinded assessors revealed additional lesions in 22%, 25% and 38% (assessor 1) and 29%, 32% and 34% (assessor 2) of patients after each cumulative dose when compared with combined T1- and T2-weighted pre-contrast images. Significantly more lesions (P! 0.01) were noted by both assessors after the first injection and by one assessor after each subsequent injection. For patients with just one lesion observed on unenhanced T1- and T2-weighted images, additional lesions were noted in 12%, 16% and 28% of patients by assessor 1 following each dose and in 24%, 27% and 30% of patients by assessor 2. Contemporaneously, diagnostic confidence was increased and lesion conspicuity improved over unenhanced MRI. For patients with one lesion observed after an initial dose of 0.05 mmol/kg, additional lesions were noted by assessors 1 and 2 in 9.1% and 11.8% of patients, respectively, after a cumulative dose of 0.1 mmol/kg and in a further 9.1% and 5.9% of patients, respectively, after a cumulative dose of 0.2 mmol/ kg. No safety concerns were apparent.
引用
收藏
页码:191 / 203
页数:13
相关论文
共 29 条
[1]   BRAIN METASTASES - COMPARISON OF GADODIAMIDE INJECTION-ENHANCED MR-IMAGING AT STANDARD AND HIGH-DOSE, CONTRAST-ENHANCED CT AND NON-CONTRAST-ENHANCED MR-IMAGING [J].
AKESON, P ;
LARSSON, EM ;
KRISTOFFERSEN, DT ;
JONSSON, E ;
HOLTAS, S .
ACTA RADIOLOGICA, 1995, 36 (03) :300-306
[2]  
AKESON P, 1995, NEURORADIOLOGY, V37, P229
[3]   Gadolinium chelates with weak binding to serum proteins - A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging [J].
Cavagna, FM ;
Maggioni, F ;
Castelli, PM ;
Dapra, M ;
Imperatori, LG ;
Lorusso, V ;
Jenkins, BG .
INVESTIGATIVE RADIOLOGY, 1997, 32 (12) :780-796
[4]   Detection of intracranial metastases - A multicenter, intrapatient comparison of gadobenate dimeglumine - Enhanced MRI with routinely used contrast agents at equal dosage [J].
Colosimo, C ;
Ruscalleda, J ;
Korves, M ;
La Ferla, R ;
Wool, C ;
Pianezzola, P ;
Kirchin, MA .
INVESTIGATIVE RADIOLOGY, 2001, 36 (02) :72-81
[5]   Brain metastases [J].
Davey, P .
CURRENT PROBLEMS IN CANCER, 1999, 23 (02) :61-+
[6]  
Ekholm S, 1996, ACTA RADIOL, V37, P223
[7]   SAFETY ASSESSMENT OF GADOPENTETATE DIMEGLUMINE IN UNITED-STATES CLINICAL-TRIALS [J].
GOLDSTEIN, HA ;
KASHANIAN, FK ;
BLUMETTI, RF ;
HOLYOAK, WL ;
HUGO, FP ;
BLUMENFIELD, DM .
RADIOLOGY, 1990, 174 (01) :17-23
[8]   Use of half-dose gadolinium-enhanced MRI and magnetization transfer saturation in brain tumors [J].
Haba, D ;
Papon, AP ;
Tanguy, JY ;
Burtin, P ;
Aube, C ;
Caron-Poitreau, C .
EUROPEAN RADIOLOGY, 2001, 11 (01) :117-122
[9]   TRIPLE-DOSE VERSUS STANDARD-DOSE GADOPENTETATE DIMEGLUMINE - A RANDOMIZED STUDY IN 199 PATIENTS [J].
HAUSTEIN, J ;
LANIADO, M ;
NIENDORF, HP ;
LOUTON, T ;
BECK, W ;
PLANITZER, J ;
SCHOFFEL, M ;
REISER, M ;
KAISER, W ;
SCHORNER, W ;
HIERHOLZER, J ;
TRAUPE, H ;
HAMM, B .
RADIOLOGY, 1993, 186 (03) :855-860
[10]   Gadobenate dimeglumine (Gd-BOPTA) - An overview [J].
Kirchin, MA ;
Pirovano, GP ;
Spinazzi, A .
INVESTIGATIVE RADIOLOGY, 1998, 33 (11) :798-809